Over the past twenty-five years, Obesity rates have spiraled to the level nearly 5 hundred million individuals worldwide. The United States leads the world, with a startling 31 % of the population being termed obese.
The health risks most commonly linked to obesity are heart attack, stroke, high blood pressure, high cholesterol, and diabetes. The annual medical costs associated with these ills are astronomical. The risk of health issues are high for those who are overweight, however, when one is obese, the chance of risk rises exponentially.
On the new product front, there is great news. Vivus Pharmaceuticals have recently announced a new weight loss pill, designated for considerable weight loss for obese patients. This groundbreaking medication is named Qsymia, aweight loss pill that was recently approved for prescription by the Food and drug administration.
The significance is that this medication was approved by the FDA this year; while the FDA has been reluctant to approve any weight loss medications in the last ten years. The pills performance has been noteworthy. Qsymia is a combination drug, consisting of two drugs, which are known to have varying degree of effectiveness with obese patients. Together is seems to be quite the combination.
As far as Food and Drug Administration commendation; clinical trials show the drug to perform markedly better than its competition's offerings. In two freestanding trial reviews; patients on Qsymia for one year, lost 6.7 per cent of their body weight in one study, and 8.9 percent in the other study. Patients on the strongest formula lost 11% of theirweight, with trial subjects reporting annual weight loss of as high as 22 pounds.
The drugs that make the weight loss pill so effective are Phentermine, an appetite suppressant and Topiramate, an anti-consultant that causes a patient to feel more satisfied after a meal. It is probable that Qsymia is effective because of its two-pronged attack on overeating.
Research also reveals that Qsymia usage correlates to lower blood pressure and the easement of other cardiovascular risks associated with obesity. There is also reported improvement in the sleep disorder known as sleep apnea.
There are certain restrictions that are assigned to Qsymia by the FDA. For example, it is only approved for use in adults. It is also restricted to use only by patients who are diagnosed as clinically obese. In addition, pregnant women are prohibited from using it. This drug must be prescribed and monitored by a physician.
Physicians and clinics on the leading edge of practice have adapted their offerings to their patients based on the results of these studies. They see this as another tool to wage battle against obesity. One such company; EquilibriumWeight loss and Longevity offers Qsymia as part of a comprehensive line of weight loss protocols.
No comments:
Post a Comment